External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

EHA 2026

June 11 - June 14

Stockholm, Sweden / Virtual (Hybrid)

ehaweb.org

Add to calendar

Medical Materials

Agenda

Coming soon

03:00 PM

Duration 15mins Stockholm

Safety and efficacy of subcutaneous mosunetuzumab▼ plus lenalidomide induction therapy followed by mosunetuzumab▼ maintenance in previously untreated follicular lymphoma

Bachy E, Morschhauser F, Eyre TA, Cordoba R, Houot R, Bishton M, Zhang HL, Zou L, Galvez-Carvajal L, Osborne W, Thieblemont C, Anz B, Knapp A, Sit J, Chang N, Hauser P, Chen V, Penuel E, Wei MC, Purev E, Patel K

Haematology - Oncology | Non-Hodgkin Lymphoma

Add to calendar

06:00 AM

Duration 90mins Stockholm, Sweden

Navigating the therapeutic pathway for diffuse large B-cell lymphoma (DLBCL): Exploring treatment sequencing with current therapies

Townsend W, Makita S, Karimi Y

Oncology | Diffuse large B cell lymphoma

Add to calendar

08:00 AM

Duration 90mins Stockholm, Sweden

Advances in the treatment of relapsed/refractory follicular lymphoma: Positioning bispecific antibodies in the treatment algorithm

Morschhauser F, Jacobson C, Bishton M, Sehn L

Haematology | Follicular Lymphoma

Add to calendar

03:30 PM

Duration 15mins Stockholm

Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: Final results of the randomized CLL14 study

Fischer K, Al-Sawaf O, Robrecht S, Giza A, Zhang C, Fink AM, Schneider C, Kreuzer KA, Chagorova T, Sivcheva L, Samoylova O, Opat S, Niemann CU, Aurer I, Bogdanov L, Schwarer A, Poulsen CB, Butler A, Loscertales Pueyo J, Owen C, Spasov E, Wrisch A, Breuleux M, Jiang Y, Jin HY, Tausch E, Schilhabel A, Ritgen M, Stilgenbauer S, Eichhorst B, Hallek M

Haematology - Oncology | Chronic Lymphocytic Leukemia

Add to calendar

04:45 PM

Duration 60mins Stockholm, Sweden

Outpatient treatment with glofitamab▼ plus gemcitabine and oxaliplatin (GemOx) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Preliminary safety results from a Phase 2 study

Yoon DH, Berz D, Carlo-Stella C, Kotb R, Lee J, Herbaux C, Puckrin R, Zeremski V, Bussot L, Musuraca G, Jagtiani R, Hernandez J, Smithen G, Prieto Gonzalez-Albo I, Lundberg L, Relf J, Burke JM

Haematology - Oncology | Diffuse large B cell lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

Five-year follow-up of patients with relapsed/refractory large B-cell lymphoma who achieved a complete response with glofitamab▼ monotherapy

Patel K, Carlo-Stella C, Hutchings M, Morschhauser F, Iacoboni G, Corradini P, Offner F, Falchi L, Mulvihill E, Breton V, Bottos A, Relf J, Lundberg L, Dickinson M, Phillips T

Haematology - Oncology | B Cell Lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

Total metabolic tumor volume and circulating tumor DNA as early prognostic factors in relapsed/refractory diffuse large B-cell lymphoma: results from the Phase 3 STARGLO trial

Townsend W, Belousov A, Abramson JS, Ku M, Huang H, Fox CP, Zhang H, Yoon DH, Kim WS, Ghesquieres H, Herbaux C, Zhang QY, Abdulhaq H, Jemaa S, Mulvihill E, Kallemeijn M, Kesavan M, Lundberg L, Bottos A, Gregory GP

Haematology - Oncology | Diffuse large B cell lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

Mosunetuzumab▼ plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in large B-cell lymphoma: Updated efficacy and safety from the Phase 3 SUNMO study including in patient subgroups

Budde EL, Westin J, Maruyama D, Zhang H, Goto H, Hong H, Fesler M, Goodgame B, Li Z, Rego EM, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, Janousek M, Pham S, Batlevi CL, Wei MC, Kim W

Haematology - Oncology | B Cell Lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

Multivariable analyses (MVAs) of overall survival (OS) in the Phase 3 SUNMO, STARGLO and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL)

Matasar M, Westin J, Abramson JS, Olszewski AJ, Pham S, Wang J, Barrett S, To I, Yin S, Batlevi C, Musick L, Lundberg L, Wei MC, Budde EL

Haematology - Oncology | B Cell Lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

Real-World Patient-Reported Treatment Burden from 106 Patients With Paroxysmal Nocturnal Hemoglobinuria: Results from the VOICE Cross-Sectional Quantitative Survey

Ueno S, Obara N, Kondo T, Ikezoe T, Fujisawa S, Sakurai M, Hosokawa K, Tashiro H, Nishiwaki K, Kitawaki T, Nishida T, Ogawa Y, Suzuki T, Kobayashi A, Yamashita M, Fukuoka Y, Murata T, Usuki K, Kawaguchi T, Hosen N, Kanakura Y, Gotoh A, Nishimura JI, Ueda Y

Haematology | Paroxysmal Nocturnal Hemoglobinuria

Add to calendar

Duration 60mins Stockholm, Sweden

3-Year Safety and Efficacy of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab: Long-Term Data From The Phase III COMMODORE 1 Trial

Şahin F, Ando K, Barcellini W, Fonseca AR, Gastal GR, Karapinar DY, Lee Y, Okan V, Soares T, Chebon S, Connor-Ahmad S, Sawai A, Sreckovic S, Clé DV

Haematology | Paroxysmal Nocturnal Hemoglobinuria

Add to calendar

Duration 60mins Stockholm, Sweden

3-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Naive to Complement Inhibitors: Long-Term Data From the Phase III COMMODORE 2 Trial

Obara N, Comia NS, Goh AS, Hantaweepant C, Jang JH, Syed Abdul Kadir SS, Rojnuckarin P, Silva F, Charania A, Chebon S, Connor-Ahmad S, Sreckovic S, Han B

Haematology | Paroxysmal Nocturnal Hemoglobinuria

Add to calendar

Duration 60mins Stockholm, Sweden

Double-blind, randomized, placebo-controlled study of crovalimab▼ as adjunct treatment for the prevention of vaso-occlusive episodes in sickle cell disease: Results from the Phase 2a CROSSWALK-C trial

Bartolucci P, Alvarenga L, Antmen B, Cancado RD, Fuh B, De Franceschi L, Glassberg J, Guvenc B, Inati A, Cela de Julián E, Karimi D, Lobo C, Lorenzetti A, Mahlangu J, Silva-Pinto A, Unal S, Castro Sánchez AY, Buatois S, Charania A, Gradinaru D, Perretti T, Lundberg P, Sreckovic S, Asirwa F

Haematology | Sickle Cell Disease

Add to calendar

Duration 60mins Stockholm, Sweden

Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial

Harkins RA, Harris W, Green M, Herrera AF, Jardin F, Lenz G, Morschhauser F, Sugidono M, Yan M, Batlevi CL, Flowers C, Jiang Y

Haematology - Oncology | Diffuse large B cell lymphoma

Add to calendar

04:45 PM

Duration 60mins Stockholm, Sweden

Cevostamab (FCRH5xCD3 bispecific antibody) induces durable responses in patients with late-line RRMM who have received prior BCMA-targeted CAR T-cell therapy: Expansion results from the CAMMA 2 study

Kumar S, Lesokhin A, Badros A, Rosinol L, Sborov D, Bertrand A, Cohen YC, Corradini P, Delforge M, Leleu X, Scheid C, Mishra A, Trunzer K, Vignal C, Cannon M, Yang A, Wassner Fritsch E, Richter J

Haematology - Oncology | Multiple Myeloma

Add to calendar

Duration 60mins Stockholm, Sweden

Fixed-duration subcutaneous mosunetuzumab▼ in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: interim analysis and patient-reported outcomes from the Phase 2 MorningSun study

Flinn IW, Burke JM, Tun AM, Ayed A, Biondo JML, Wu M, Hossain F, Mun Y, Farighi R, Singh A, Misleh J, Peles S, Budde EL, Villasboas JC, Sharman JP

Haematology - Oncology | Diffuse large B cell lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

Durable remissions with glofitamab▼ plus polatuzumab vedotin in relapsed/refractory large B-cell lymphoma (LBCL), including elderly patients and those with high-grade B-cell lymphoma (HGBCL)

Gritti G, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, Jørgensen J, Zinzani PL, Gurion R, Goldschmidt N, Leung W, Relf J, Barrier R, Tandon M, Kallemeijn MJ, Sellam G, Hutchings M

Haematology - Oncology | B Cell Lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

3-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) Who Switched From Ravulizumab: Long Term Data from the Phase III COMMODORE 1 Trial

Ueda Y, Alzahrani H, Contento Gonzalo A, Höglund M, Kim JS, Kulasekararaj AG, Panse J, Rose MJ, Schubert J, Yap ES, Chebon S, Connor-Ahmad S, Li S, Sreckovic S, Scheinberg P

Haematology | Paroxysmal Nocturnal Hemoglobinuria

Add to calendar

Duration 60mins Stockholm, Sweden

Double-blind, randomized, placebo-controlled study of crovalimab▼ for the treatment of acute vaso-occlusive episodes in sickle cell disease: Results of the Phase 1b CROSSWALK-A trial

Chonat S, Fiscina Alvarenga LS, Chite Asirwa F, De Franceschi L, Cela de Julián E, Karimi D, Mahlangu J, Nur E, Okoli S, Payán-Pernía S, Schimmel J, Taher A, Buatois S, Castro Sánchez AY, Charania A, Hsia A, Sreckovic S, Yin A, Bartolucci P

Haematology | Sickle Cell Disease

Add to calendar

Duration 60mins Stockholm, Sweden

CELESTIMO single arm extension: Safety and efficacy of mosunetuzumab▼ plus lenalidomide in patients with R/R follicular lymphoma

Budde EL, Sano D, Bartlett N, Wagner-Johnston N, Brinker B, Vaidya R, Babu S, Nze C, Pearson E, McKinney M, Zhuo Y, Birhiray R, Kornblum N, Penuel E, Ma CY, Knapp A, Doral M, Chen V, Hauser P, Wei MC, Purev E, Diefenbach C

Haematology - Oncology | Follicular Lymphoma

Add to calendar

Duration 60mins Stockholm, Sweden

Maintenance of health-related quality of life with venetoclax-obinutuzumab vs chemoimmunotherapy in fit patients with previously untreated chronic lymphocytic leukemia from the Phase 3 CRISTALLO trial

Morschhauser F, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Singh A, Jin HY, Thadani-Mulero M, Breuleux M, Egginton A, Trask P, Sharman JP

Haematology - Oncology | Chronic Lymphocytic Leukemia

Add to calendar

09:30 AM

Duration 15mins Stockholm

Fixed-duration glofitamab▼ monotherapy in relapsed or refractory mantle cell lymphoma with or without prior Bruton's tyrosine kinase inhibitor exposure: Updated outcomes with 3.5 year follow-up

Karimi YH, Hutchings M, Phillips T, Trneny M, Dickinson M, Offner F, Morschhauser F, Bachy E, Bartlett NL, Brody J, Zaucha J, Wrobel T, Gil L, Breton V, Negricea R, Kallemeijn M, Berthier A, Leung W, Sellam G, Lundberg L, Carlo-Stella C

Haematology - Oncology | Mantle Cell Lymphoma

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.